CD4 and rheumatoid arthritis: Thirteen out of the 14 patients with pSTAT3+ CD4+ T cells at baseline reached a good EULAR treatment response and one patient was a non-responder (Table 1, Fig 2) indicating that presence of pSTAT3+ CD4+ T cells in early RA may serve as predictor of good treatment response.